Hold Cipla, says Shahina Mukadam

Shahina Mukadam, Independent Market Expert told CNBC-TV18, "Cipla, I think there is nothing a miss in the numbers. They are pretty much in-line. I think the margins that you have highlighted at 19 percent, is pretty good. The management commentary also we saw recently of a 10 percent growth and margin improvement continuing through operational efficiency, if that continues, I think the numbers are well in-line and the company is well in-line to do a EPS of almost Rs 25 for the year which gives you a multiple of around maybe slightly over 20."

"I think that could be the only reason and the sharp run up of the stock price and of course the Lupin news. I think these three factors could be the ones that are contributing to the softness in the stock price today, the stock that has come off. However, otherwise if you see, most analysts have got a buy on the stock and the mood is pretty upbeat on Cipla per se."

"Also if you look at the future, I think the inhaler launch that is planned in developed markets over a medium, one to two years, will be a very big pickup. So if you are a long term investor, I would suggest continue holding, but I think the support levels are pretty close. So one needs to keep a watch and then relook at the price because at current levels, given the current state, below Rs 620, at these level it could slip further. So maybe if an investor is looking to get out and re- enter, that possibility exists," she added.